Browse the evidence

Combining GLP-1 receptor agonists (GLP-1RAs) with lifestyle modifications results in significantly greater weight loss and improved cardiometabolic biomarkers compared to lifestyle modifications alone in adults with overweight or obesity.

If you have overweight or obesity, combining a GLP-1 receptor agonist (like semaglutide or liraglutide) with lifestyle changes (calorie restriction and regular exercise) is significantly more effective for weight loss and improving heart health markers than lifestyle changes alone. To minimize muscle loss, ensure your lifestyle intervention includes resistance training. Consult a doctor to determine if GLP-1RAs are appropriate for you.

Spirulina supplementation (3000 mg/day) during a 12-day gradual weight loss protocol significantly enhances fat mass loss and body fat percentage reduction compared to placebo in competitive wrestlers, while maintaining skeletal muscle mass and reducing catabolic myostatin levels.

If you are a wrestler cutting weight, adding 3 grams of spirulina daily (split into 3 doses before meals) to your gradual weight loss diet can help you lose more fat than dieting alone. In this study, wrestlers taking spirulina lost significantly more fat mass and body fat percentage over 12 days compared to those taking a placebo. However, spirulina did not prevent muscle loss; both groups lost similar amounts of muscle. To preserve muscle, ensure your protein intake is high (1.6-3.1 g/kg/day) alongside the spirulina and diet.

Spirulina supplementation during gradual weight loss significantly reduces serum myostatin (MST) and liver enzymes (AST, ALT) compared to placebo, suggesting a protective effect on the liver and a reduction in the catabolic environment.

Spirulina supplementation (3g/day) during your weight cut may help protect your liver and reduce catabolic stress. The study showed significant reductions in liver enzymes (AST, ALT) and myostatin (a hormone that limits muscle growth) in wrestlers taking spirulina compared to placebo. This suggests spirulina may help create a less catabolic environment during weight loss.

Treatment with tirzepatide (10 or 15 mg) produces a significantly greater reduction in predicted 10-year cardiovascular disease (CVD) risk compared to semaglutide (1.7 or 2.4 mg) in individuals with obesity without diabetes or prior CVD.

If you have obesity and are at risk for heart disease but don't have diabetes, tirzepatide may offer better long-term heart protection than semaglutide. It is taken as a weekly injection and has been shown to reduce your predicted 10-year risk of cardiovascular events more than semaglutide. Discuss with your doctor if this medication is appropriate for your specific health profile.

Intensive glycemic control (HbA1c <6.5%) in the first year after diagnosis of Type 2 Diabetes significantly reduces the 10-year risk of microvascular and macrovascular complications compared to higher HbA1c levels.

If you were just diagnosed with Type 2 Diabetes, ask your doctor about getting your blood sugar under tight control (HbA1c <6.5%) as soon as possible. This early, intensive treatment significantly reduces your risk of developing serious complications like kidney disease, heart problems, and vision loss over the next 10 years.

Tirzepatide treatment produces significant body weight, waist circumference, and waist-to-height ratio reductions in women across all reproductive stages (premenopausal, perimenopausal, and postmenopausal), demonstrating efficacy irrespective of menopausal status.

If you are a woman with overweight or obesity, whether you are premenopausal, perimenopausal, or postmenopausal, tirzepatide (15mg weekly) is highly effective for significant weight loss. Do not assume your reproductive stage limits your ability to lose weight with this treatment; the data shows robust results across all stages.

GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and emerging triple agonists (e.g., retatrutide) significantly reduce body weight, improve glycemic control, and reverse hepatic steatosis in patients with obesity and type 2 diabetes.

GLP-1 and GIP/GLP-1 agonists (like semaglutide and tirzepatide) are highly effective for weight loss and reversing liver fat in people with obesity and diabetes. They work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. Triple agonists (like retatrutide) are showing even greater promise for liver fat normalization.

Tirzepatide 15 mg once weekly produces statistically significant greater reductions in body weight, BMI, and HbA1c compared to semaglutide 2.4 mg once weekly in patients with type 2 diabetes and obesity/overweight.

For patients with type 2 diabetes and obesity, tirzepatide 15mg once weekly is a more effective option for weight loss and blood sugar control than semaglutide 2.4mg. This treatment must be combined with a reduced-calorie diet and regular physical activity. Patients should be aware that while tirzepatide 15mg is more effective, it may have a slightly higher risk of gastrointestinal side effects compared to semaglutide 10mg, though both are generally well-tolerated.

Tirzepatide 15 mg provides statistically significant improvements in cardiometabolic risk factors, including waist circumference, fasting plasma glucose, and triglycerides, compared to semaglutide 2.4 mg.

Beyond weight loss, tirzepatide 15mg offers superior benefits for heart health markers like waist size, blood sugar (fasting), and triglycerides compared to semaglutide 2.4mg. This makes it a strong option for patients concerned about cardiovascular risk factors associated with obesity and diabetes.

GLP-1 analogues (e.g., semaglutide) and dual agonists (e.g., tirzepatide) produce robust weight loss (15-21%) that approaches or exceeds bariatric surgery efficacy, with potential independent cardiovascular benefits beyond weight loss.

For patients with obesity who have not achieved sufficient weight loss with lifestyle changes alone, consider GLP-1 analogues like semaglutide (2.4 mg weekly) or dual agonists like tirzepatide. These medications can produce 15-21% weight loss, approaching the efficacy of bariatric surgery, and may offer independent cardiovascular benefits.

Heavy-load resistance training preserves lean body mass in prostate cancer patients undergoing androgen deprivation therapy (ADT), effectively counteracting the muscle loss typically caused by the therapy, while simultaneously increasing muscle strength to a degree comparable to healthy elderly men.

If you are undergoing hormone therapy for prostate cancer, do not skip resistance training. Heavy lifting (using weights that feel hard for 6-12 reps, 2-3 times a week) will help you keep the muscle you have and make you stronger. You might not see your muscles get bigger like a healthy person would, but you will stop them from shrinking, which is a major win for your health and survival.

Tirzepatide 15 mg once weekly is preferred for individuals with obesity and heart failure with preserved ejection fraction (HFpEF) to improve symptoms and functional capacity, irrespective of glycemic status or weight loss magnitude.

If you have obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce hospitalizations and improve your ability to walk and feel better, even if your blood sugar is normal or you don't lose a lot of weight.

Multireceptor incretin agonists (targeting GLP-1, GIP, and/or Glucagon receptors) produce clinically meaningful weight loss by simultaneously suppressing appetite via central nervous system pathways and increasing energy expenditure via peripheral metabolic activation.

If you have obesity, relying on willpower and diet alone often fails because your body fights back by slowing your metabolism and increasing hunger. Modern incretin-based medications work by targeting specific hormone receptors to simultaneously turn off the drive to eat and turn up your energy expenditure. This dual approach addresses the physiological root of obesity, offering significantly higher weight loss potential than lifestyle changes alone, with newer formulations designed to minimize side effects like nausea.

First-line GLP-1 RA initiation is associated with greater HbA1c reduction compared to metformin in both patients with prediabetes and diabetes.

GLP-1 RA is more effective than metformin at lowering HbA1c levels in both prediabetes and diabetes. This makes it a potent option for achieving glycemic targets, though adherence should be monitored.

Tirzepatide produces significantly greater weight loss than semaglutide in patients with type 2 diabetes, with a mean difference of -4.84 kg favoring tirzepatide.

If you have Type 2 Diabetes and are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is likely to produce greater weight loss (approx. 4.8 kg more on average). Both drugs share similar gastrointestinal side effect profiles, which are generally manageable. The choice may depend on individual response, tolerability, and cost/insurance coverage, but Tirzepatide shows superior efficacy in head-to-head comparisons.

GLP-1 and GIP receptor agonists (semaglutides and tirzepatides) effectively reverse overweight, obesity, and type 2 diabetes by targeting neuro-hormonal pathways, achieving mean weight reductions of 10.2% and 15.0% respectively, whereas lifestyle interventions fail to produce permanent weight loss due to compensatory biological mechanisms.

If you have struggled to maintain weight loss through diet and exercise alone, recognize that this is likely due to biological resistance (hormonal signals), not a lack of willpower. Consult a healthcare provider about GLP-1/GIP agonists (like semaglutide or tirzepatide), which target these specific pathways. While currently expensive, these treatments offer a clinically proven path to significant weight loss and diabetes management that lifestyle changes alone have failed to provide for most people.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) offer superior weight loss compared to older anti-obesity medications.

Newer injectable medications like Semaglutide and Tirzepatide provide significantly greater weight loss than older drugs. They are taken weekly and are highly effective, but access and cost can be barriers.

Next-generation multi-receptor agonists (e.g., Tirzepatide, a dual GLP-1/GIP agonist) offer superior weight loss and metabolic efficacy compared to single GLP-1RAs.

If single GLP-1 medications (like Ozempic or Wegovy) aren't providing enough weight loss or metabolic improvement, ask your doctor about dual-agonists like Tirzepatide. These newer drugs target two hormones (GLP-1 and GIP) and have shown even greater weight loss in clinical trials. They are approved for both diabetes and obesity management.

GCGR/GLP-1 dual agonists (e.g., mazdutide, survodutide) and GCGR/GLP-1/GIP triple agonists (e.g., retatrutide) elicit substantial body weight reduction (up to 24.2%) and improve liver health in patients with obesity and MASLD/MASH.

For individuals with obesity and liver fat, newer once-weekly injections targeting the glucagon and GLP-1 receptors (and sometimes GIP) are showing remarkable results, with some patients losing over 20% of their body weight and seeing improvements in liver health. These are prescription medications requiring medical supervision, but they represent a significant advancement over older treatments.

Semaglutide (2.4 mg once-weekly) significantly reduces the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its components (steatosis, inflammation, ballooning) in patients with overweight/obesity and type 2 diabetes compared to placebo.

If you have overweight/obesity and type 2 diabetes, semaglutide (2.4 mg weekly) is a clinically proven treatment to significantly reduce liver fat, inflammation, and scarring (MASH/MASLD) compared to placebo. This is particularly relevant if lifestyle changes alone have not resolved liver issues. The treatment involves a weekly injection and is supported by strong statistical evidence from large clinical trials.

Retatrutide (12mg weekly) achieves 24.2% weight loss, rivaling bariatric surgery outcomes.

Retatrutide 12mg weekly can lead to ~24% weight loss. This is the highest efficacy reported in this review, rivaling surgery.

CagriSema (Cagrilintide + Semaglutide) achieves 22.7% weight loss, outperforming semaglutide alone.

CagriSema, a combination of Cagrilintide and Semaglutide, can lead to ~23% weight loss. It is more effective than Semaglutide alone.

GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.

GLP-1 based medications like tirzepatide are highly effective for weight loss (15-21%) and blood sugar control. Be aware that gastrointestinal side effects are common and may lead some to stop treatment, but the dual benefit is significant. Discuss dosing strategies with your provider to manage side effects.

Utilization of Glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes is a significant independent predictor of achieving relevant weight loss (≥7%) in MASLD patients, with odds ratios increasing for greater weight loss thresholds.

If you have MASLD and Type 2 Diabetes, using a GLP-1 agonist significantly increases your chances of losing enough weight to improve your liver health. The data shows that users are over 4 times more likely to lose 10% or more of their body weight compared to non-users. Discuss this option with your doctor as part of a comprehensive MASLD management plan.